Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 194 clinical trials
Featured trial
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.  

daratumumab
refractory multiple myeloma
  • 186 views
  • 10 May, 2022
  • 28 locations
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years. Given that myeloma remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options for …

  • 58 views
  • 21 Jan, 2021
  • 3 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 0 views
  • 06 May, 2022
  • 18 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 0 views
  • 15 May, 2022
  • 18 locations
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of …

ixazomib
refractory multiple myeloma
cancer
immunoglobulin
ejection fraction
  • 35 views
  • 16 Feb, 2022
  • 2 locations
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at

  • 1 views
  • 25 Mar, 2022
  • 1 location
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma

  • 0 views
  • 22 Mar, 2022
  • 1 location
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to

  • 0 views
  • 25 Mar, 2022
  • 1 location
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options

  • 0 views
  • 23 Mar, 2022
  • 1 location
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

  • 0 views
  • 11 May, 2022
  • 2 locations